Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve.
Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve.
复制标题
DOI：
10.1038/s43856-021-00039-7
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Zipeto, Donato
中科院分区：
文献类型：
--
作者：
Dalle Carbonare, Luca;Valenti, Maria Teresa;Bisoffi, Zeno;Piubelli, Chiara;Pizzato, Massimo;Accordini, Silvia;Mariotto, Sara;Ferrari, Sergio;Minoia, Arianna;Bertacco, Jessica;Li Vigni, Veronica;Dorelli, Gianluigi;Crisafulli, Ernesto;Alberti, Daniela;Masin, Laura;Tiberti, Natalia;Longoni, Silvia Stefania;Lopalco, Lucia;Beretta, Alberto;Zipeto, Donato
SARS-CoV-2感染后免疫力下降的个体对SARS-CoV-2mRNA疫苗的抗体反应，以及既往感染和幼稚个体的IgA和IgM反应模式仍然知之甚少。我们对免疫幼稚(N，n = 50)或在意大利第一次(n = 25)和第二次(n = 26)大流行期间感染过 = -2(P.I.，n SARS 51)的BTN162b2mRNA疫苗接受者进行了血清学研究。免疫前、第一、二次免疫后采集血清，检测S抗SARS-CoV-2刺突抗体、抗N蛋白抗体及血清中和活性。第一波流行中抗体滴度下降的大多数P.I.对第一针免疫球蛋白-S和假病毒中和滴度的应答显著高于第二针后观察到的N人。在所有受者中，单剂疫苗足以诱导与血清中和滴度无关的有效IgA反应。我们观察到了一种非常规的IgM反应模式，即使在第二次接种疫苗后，也只有一半免疫幼稚的受试者产生了这种反应。P.I.个体对单剂疫苗的反应比在两剂疫苗后观察到的N个体的反应更强。疫苗诱导的IgA与血清中和无关。Dalle Carbonare等人。对既往感染过SARS-CoV-2的参与者和接受过两剂辉瑞生物科技BNT162b2疫苗的SARS-CoV-2幼稚患者进行血清学研究。在单剂注射后，他们观察到以前感染过病毒的参与者更快地回忆起假病毒中和滴度，两组中都出现了与血清中和滴度无关的强大的IgA反应。抗体是免疫系统产生的蛋白质，释放到血液中，帮助对抗感染。为了了解之前感染过SARS-CoV-2的人接种新冠肺炎疫苗后免疫系统的反应，我们比较了第一次和第二次接种疫苗后产生的抗体类型和水平，并与从未感染过的人进行了比较。我们发现，一剂疫苗，即使在感染几个月后，也足以通过诱导特定类型的抗体来增强非常有效的反应，其中一些是中和病毒的，另一些是不能中和病毒的。我们还观察到，在几乎一半没有感染的人中，有一种不寻常的抗体图谱。这些发现可能有助于更好地了解新冠肺炎疫苗的免疫反应。
The antibody response to SARS-CoV-2 mRNA vaccines in individuals with waning immunity generated by a previous SARS-CoV-2 infection, as well as the patterns of IgA and IgM responses in previously infected and in naïve individuals are still poorly understood. We performed a serology study in a cohort of BTN162b2 mRNA vaccine recipients who were immunologically naïve (N, n = 50) or had been previously infected with SARS-CoV-2 (P.I., n = 51) during the first (n = 25) or second (n = 26) pandemic waves in Italy, respectively. We measured IgG, IgM and IgA antibodies against the SARS-CoV-2 Spike (S) and IgG against the nucleocapsid (N) proteins, as well as the neutralizing activity of sera collected before vaccination, after the first and second dose of vaccine. Most P.I. individuals from the first pandemic wave who showed declining antibody titres responded to the first vaccine dose with IgG-S and pseudovirus neutralization titres that were significantly higher than those observed in N individuals after the second vaccine dose. In all recipients, a single dose of vaccine was sufficient to induce a potent IgA response that was not associated with serum neutralization titres. We observed an unconventional pattern of IgM responses that were elicited in only half of immunologically naïve subjects even after the second vaccine dose. The response to a single dose of vaccine in P.I. individuals is more potent than that observed in N individuals after two doses. Vaccine-induced IgA are not associated with serum neutralization. Dalle Carbonare et al. perform a serology study in participants with a prior infection of SARS-CoV-2 and those who are SARS-CoV-2-naïve, who received two doses of the Pfizer-BioNTech BNT162b2 vaccine. After a single dose they observe a quicker recall of pseudovirus neutralization titres in previously-infected participants and a potent IgA response in both groups that was not associated with serum neutralization titres. Antibodies are proteins produced by the immune system that are released into the bloodstream and help fight infections. To understand how the immune system responds to COVID-19 vaccination in individuals who have had a previous SARS-CoV-2 infection, we compared the types and levels of antibodies produced after first and second doses of the vaccine with those of individuals who had never been infected. We found that one dose of vaccine, even several months after the infection, was sufficient to boost a very efficient response by eliciting specific types of antibodies, some of which were and some that were not able to neutralize the virus. We also observed an unusual antibody profile in almost half of individuals who had not been infected. These findings may help better understand the immune response to COVID-19 vaccines.